Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...
November 13, 2024—R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the company’s ELITE-BTK pivotal trial of Magnitude, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback